The study of novel DNA vaccines against tuberculosis

References

• Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191 - 204; http://dx.doi.org/10.1016/j.vaccine.2005.08.103; PMID: 16216394
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol 2011; 2011:549281; http://dx.doi.org/10.1155/2011/549281; PMID: 21437226
   PubMed Web of Science ®Google Scholar
• Boom WH. New TB vaccines: is there a requirement for CD8 T cells?. J Clin Invest 2007; 117:2092 - 4; http://dx.doi.org/10.1172/JCI32933; PMID: 17671648
   PubMed Web of Science ®Google Scholar
• van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30:3689 - 98; http://dx.doi.org/10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4; PMID: 11169412
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 2007; 25:2990 - 3; http://dx.doi.org/10.1016/j.vaccine.2007.01.014; PMID: 17280753
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y. Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. Hum Vaccin 2010; 6:297 - 308; http://dx.doi.org/10.4161/hv.6.4.10172; PMID: 20372079
   PubMed Web of Science ®Google Scholar
• Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430 - 6; http://dx.doi.org/10.1038/nm0496-430; PMID: 8597953
   PubMed Web of Science ®Google Scholar
• Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132 - 5; http://dx.doi.org/10.1016/j.vaccine.2005.01.057; PMID: 15755583
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267 - 70; http://dx.doi.org/10.1016/j.vaccine.2009.01.064; PMID: 19200841
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin 2011; 7:Suppl 60 - 7; http://dx.doi.org/10.4161/hv.7.0.14563; PMID: 21546794
   PubMed Web of Science ®Google Scholar
• Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin 2011; 7:Suppl 108 - 14; http://dx.doi.org/10.4161/hv.7.0.14571; PMID: 21263229
   PubMed Web of Science ®Google Scholar
• Stegelmann F, Bastian M, Swoboda K, Bhat R, Kiessler V, Krensky AM, et al. Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8+ T cells provides a host defense mechanism against Mycobacterium tuberculosis. J Immunol 2005; 175:7474 - 83; PMID: 16301655
   PubMed Web of Science ®Google Scholar
• Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. Crit Rev Immunol 2006; 26:317 - 52; http://dx.doi.org/10.1615/CritRevImmunol.v26.i4.30; PMID: 17073557
   PubMed Web of Science ®Google Scholar
• Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, et al. Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol 2001; 166:439 - 46; PMID: 11123322
   PubMed Web of Science ®Google Scholar
• Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121 - 5; http://dx.doi.org/10.1126/science.282.5386.121; PMID: 9756476
   PubMed Web of Science ®Google Scholar
• Castiello L, Stroncek DF, Finn MW, Wang E, Marincola FM, Clayberger C, et al. 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. J Transl Med 2011; 9:41; http://dx.doi.org/10.1186/1479-5876-9-41; PMID: 21501511
   PubMed Web of Science ®Google Scholar
• Clayberger C, Finn MW, Wang T, Saini R, Wilson C, Barr VA, et al. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity. J Immunol 2012; 188:6119 - 26; http://dx.doi.org/10.4049/jimmunol.1200570; PMID: 22586033
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240 - 4; http://dx.doi.org/10.1038/nm1128; PMID: 15502839
   PubMed Web of Science ®Google Scholar
• Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, et al. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. Vaccine 2008; 26:5269 - 75; http://dx.doi.org/10.1016/j.vaccine.2008.07.040; PMID: 18682270
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375:2110 - 9; http://dx.doi.org/10.1016/S0140-6736(10)60393-5; PMID: 20488515
   PubMed Web of Science ®Google Scholar
• Rahman S, Magalhaes I, Rahman J, Ahmed RK, Sizemore DR, Scanga CA, et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates. Mol Med 2012; 18:647 - 58; http://dx.doi.org/10.2119/molmed.2011.00222; PMID: 22396020
   PubMed Web of Science ®Google Scholar
• Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001; 166:6404 - 12; PMID: 11342666
   PubMed Web of Science ®Google Scholar
• Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 2010; 5:e13837; http://dx.doi.org/10.1371/journal.pone.0013837; PMID: 21079801
   PubMedGoogle Scholar
• Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8:2133 - 41; http://dx.doi.org/10.1089/hum.1997.8.17-2133; PMID: 9414261
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219 - 26; http://dx.doi.org/10.1006/mthe.2002.0647; PMID: 12161188
   PubMed Web of Science ®Google Scholar
• Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003; 4:599 - 602; http://dx.doi.org/10.2174/1389450033490740; PMID: 14577648
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53:307 - 32; http://dx.doi.org/10.1016/S0065-2660(05)53012-8; PMID: 16240999
   PubMed Web of Science ®Google Scholar
• Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044 - 52; http://dx.doi.org/10.1002/jgm.753; PMID: 15756713
   PubMed Web of Science ®Google Scholar
• Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-05-0352; PMID: 16648574
   PubMed Web of Science ®Google Scholar
• Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci U S A 1981; 78:7717 - 21; http://dx.doi.org/10.1073/pnas.78.12.7717; PMID: 6801660
   PubMed Web of Science ®Google Scholar
• Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335 - 43; PMID: 9102222
   PubMed Web of Science ®Google Scholar
• Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583 - 90; http://dx.doi.org/10.1084/jem.157.2.583; PMID: 6600487
   PubMed Web of Science ®Google Scholar
• Okada M, Klimpel GR, Kuppers RC, Henney CS. The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is Lyt 1 + cell dependent. J Immunol 1979; 122:2527 - 33; PMID: 156228
   PubMed Web of Science ®Google Scholar
• Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583 - 90; http://dx.doi.org/10.1084/jem.157.2.583; PMID: 6600487
   PubMed Web of Science ®Google Scholar